Sponsored by
Small-Cap Investing
  •  

A BABY's Got to Grow

By Brian Orelli May 14, 2008 Comments (0)

7 Recommendations

When a company does a secondary stock offering, it means one of two things: The company is suffering and needs to raise cash, or it's growing quickly and needs to raise cash. Both can be a scary proposition, but if you have confidence in management, the latter shouldn't cause the value of the company to shrink and might present a buying opportunity if other investors decide to sell.

Take, for instance, Natus Medical (Nasdaq: BABY). Last night the company announced that it is selling an additional 3.5 million shares -- possibly more than 4 million with the over allotment -- and shares sank more than 5%. "Hogwash," say I.

Yes, I know the company sold almost 900,000 shares last month, but the Motley Fool Hidden Gems pick has proven that it can make strategic purchases at reasonable prices. Its most recent acquisition, Sonomed, is being bought at just 1.8 times annual sales based on the expected $6.3 million purchase price, and Sonomed earns gross margins close to 75%. Compare that to Natus, which has a market cap of about 3.6 times its trailing revenue on gross margins hovering around 63%.

Yet CEO Jim Hawkins characterizes the purchase as "a little more than the typical amount we pay." You've got to love tightwad CEOs.

Compare that to other acquisitions and partnerships in the health-care field that are a long way from benefiting the company opening up its coffers. There's GlaxoSmithKline's (NYSE: GSK) acquisition of Sirtris Pharmaceuticals (Nasdaq: SIRT) and Pfizer's (NYSE: PFE) partnership with Avant Immunotherapeutics (Nasdaq: AVAN), for example.

Natus' acquisitions, on the other hand, usually have an immediate impact. By design. During last quarter's conference call, management said that it "look[s] for ... acquisitions to be immediately accretive in the first full quarter after acquisition." Tightwad CEOs that know how to grow earnings are great.

With management having a tight grip on the company's coffers, shareholders shouldn't be worried about the share dilution. Yes, they'll own a slightly smaller piece of the pie, but if Natus invests the money Foolishly, as it seems to have done so far, the pie will be much larger.

Get the best of the Fool delivered to your inbox every Friday

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 645160, ~/articles/articlehandler.aspx, 7/24/2008 8:07:03 AM,

Sign up for FREE Motley Fool site access!

Already registered? Login Here

It’s FREE! Enter your email address, and we’ll rush you to the article you're looking for right now.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Related Tickers

Natus Medical, Inc.

BABY Up! $23.56 +0.63 (+2.75%) 4:00 PM
CAPS Rating:
1241 Outperforms
32 Underperforms
Rate This Stock

Major Indices

S&P 5001,282.19+0.41%
DJIA11,632.38+0.26%
RSL 2K719.19+0.33%
NASD2,325.88+0.95%
Updated: 4:02:47 PM
Sponsored by:

The Motley Poll

What company will see the next Bear Stearns-style implosion?

Sponsored by: